The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma : Anti-Cancer Drugs

Journal Logo

CLINICAL REPORTS

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

Iacovelli, Robertoa; Cossu Rocca, Mariab; Galli, Lucae; Sabbatini, Robertof; De Giorgi, Ugog; Santini, Danieleh; Facchini, Gaetanoi; Mosca, Alessandraj; Atzori, Francescok; Zucali, Paoloc; Fornarini, Giuseppel; Massari, Francescom; Buti, Sebastianon; Ricotta, Riccardod; Masini, Cristinao; Toscani, Ilariap; Biasco, Elisae; Guida, Annalisaf; Lolli, Cristiang; De Lisi, Deliah; Rossetti, Sabrinai; Terrone, Carloj; Scartozzi, Mariok; Miggiano, Chiarac; Pastorino, Alessandrol; Bersanelli, Melissan; Carlo-Stella, Giuliad; Pinto, Carmineo; Nobili, Elisabettam; Nolè, Francob; Tortora, Giampaoloa; Porta, Camillop

Author Information
Anti-Cancer Drugs 29(7):p 705-709, August 2018. | DOI: 10.1097/CAD.0000000000000632

Abstract

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid